Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRI NASDAQ:ELAB NASDAQ:IMCC NASDAQ:PHXM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.92-2.2%$0.93$0.54▼$2.22$9.34M0.53240,952 shs148,625 shsELABPMGC$8.61+65.3%$5.78$4.28▼$901.60$3.59M0.32496,608 shs18.26 million shsIMCCIM Cannabis$1.95+0.2%$2.16$1.29▼$7.12$10.26M2.13108,751 shs22,595 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera-1.88%-11.13%+11.98%+14.86%+17.75%ELABPMGC-4.75%-3.70%+9.00%-35.00%-98.87%IMCCIM Cannabis+1.04%-5.80%-1.02%-37.30%-13.72%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.92-2.2%$0.93$0.54▼$2.22$9.34M0.53240,952 shs148,625 shsELABPMGC$8.61+65.3%$5.78$4.28▼$901.60$3.59M0.32496,608 shs18.26 million shsIMCCIM Cannabis$1.95+0.2%$2.16$1.29▼$7.12$10.26M2.13108,751 shs22,595 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera-1.88%-11.13%+11.98%+14.86%+17.75%ELABPMGC-4.75%-3.70%+9.00%-35.00%-98.87%IMCCIM Cannabis+1.04%-5.80%-1.02%-37.30%-13.72%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 2.00Hold$2.75198.59% UpsideELABPMGC 1.00SellN/AN/AIMCCIM Cannabis 1.00SellN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ELAB, IMCC, PHXM, and BFRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BFRIBiofronteraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ELABPMGCWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025IMCCIM CannabisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BFRIBiofronteraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ELABPMGCWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025IMCCIM CannabisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$37.32M0.25N/AN/A$0.57 per share1.62ELABPMGC$1.71M2.12N/AN/A$40.36 per share0.21IMCCIM Cannabis$39.44M0.26N/AN/A$1.03 per share1.90PHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$17.76M-$2.26N/AN/AN/A-42.34%-1,104.09%-82.28%11/12/2025 (Estimated)ELABPMGC-$6.25M-$433.87N/A∞N/AN/A-62.73%-52.83%11/12/2025 (Estimated)IMCCIM Cannabis-$7.72M-$0.54N/AN/AN/A-4.19%-59.80%-5.15%11/13/2025 (Estimated)PHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ALatest ELAB, IMCC, PHXM, and BFRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025BFRIBiofrontera-$0.45-$0.57-$0.12-$0.57$8.30 million$9.03 million8/12/2025Q2 2025IMCCIM Cannabis-$0.1367-$0.0653+$0.0714-$0.07$12.88 million$9.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/AELABPMGCN/AN/AN/AN/AN/AIMCCIM CannabisN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofrontera8.990.960.75ELABPMGCN/A22.4022.40IMCCIM Cannabis0.320.720.62PHXMPHAXIAM Therapeutics0.231.78N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%ELABPMGC22.22%IMCCIM Cannabis7.68%PHXMPHAXIAM Therapeutics0.40%Insider OwnershipCompanyInsider OwnershipBFRIBiofrontera4.80%ELABPMGC0.24%IMCCIM CannabisN/APHXMPHAXIAM Therapeutics1.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera7010.14 million9.65 millionNo DataELABPMGC18420,000424,000N/AIMCCIM Cannabis3405.25 millionN/ANot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataELAB, IMCC, PHXM, and BFRI HeadlinesRecent News About These CompaniesPHXM.FR | Phaxiam Therapeutics S.A. Annual Income Statement - WSJJuly 18, 2025 | wsj.comPhaxiam Therapeutics SA (PHXM) Stock Forums - Investing.comJune 27, 2025 | investing.comPHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until DelistingJune 18, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces Judicial Liquidation and DelistingJune 13, 2025 | finance.yahoo.comPHAXIAM Therapeutics: New Postponement of the Offer Review HearingJune 5, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Postponement of the Offer Review HearingMay 23, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Extension of the Observation Period of the Receivership ProcedureMay 5, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Update on the Receivership ProcedureApril 25, 2025 | finance.yahoo.comPhaxiam Therapeutics S.A.March 28, 2025 | wsj.comPHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership ProcedureMarch 15, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results PublicationMarch 6, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Press Release Regarding Suspension of TradingMarch 6, 2025 | finance.yahoo.comPHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage TherapyJanuary 31, 2025 | businesswire.comPHAXIAM Therapeutics Announces Its Financial Calendar for 2025January 13, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in EuropeJanuary 7, 2025 | finance.yahoo.comPHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical StudyDecember 30, 2024 | finance.yahoo.comPHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy areaNovember 27, 2024 | globenewswire.comPHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"November 18, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | finanznachrichten.dePHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELAB, IMCC, PHXM, and BFRI Company DescriptionsBiofrontera NASDAQ:BFRI$0.92 -0.02 (-2.23%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.PMGC NASDAQ:ELAB$8.61 +3.40 (+65.32%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.IM Cannabis NASDAQ:IMCC$1.95 +0.00 (+0.21%) As of 11:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 10/10/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
